Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
July 01, 2009 (Vol. 29, No. 13)

Fluidics-Free Molecular Interactions Analysis

ForteBio’s Dip and Read Method Simplifies Label-Free Assays

  • Small Molecules

    Click Image To Enlarge +
    Figure 2. Analysis of known inhibitors binding to carbonic anhydrase

    Kinetic analysis of small drug-like molecules binding to protein targets is a crucial aspect of drug discovery. Small molecules present several unique challenges for interaction analysis. Most obvious is their size, which is typically less than 500 daltons, resulting in small binding signals and low signal to noise. They also exhibit fast association and dissociation rates with proteins, the accurate measurement of which can be challenging. In addition, small molecules are generally less soluble in standard aqueous buffers than proteins and require the addition of organic co-solvents such as DMSO. 

    To combat the low signal to noise seen in small molecule experiments, two pathways have been pursued simultaneously. New super streptavidin (SSA) coated biosensors with increased binding capacity for biotinylated capture molecules increase signal three- to eightfold depending on the molecular system. In addition, higher sensitivity spectrometers allow the newest Octet instruments (Octet RED and Octet RED384) to have an eight- to tenfold reduction in noise. Together, the two approaches have enabled the analysis of binding kinetics of small molecules as small as 157 daltons.

    The use of cosolvents at levels that are compatible with most proteins (1–5% DMSO) are easily tolerated in BLI-based analysis, but should be kept consistent throughout the assay. In Figure 2, kinetic analyses of three different known inhibitors for carbonic anhydrase are shown. Biotinylated carbonic anhydrase was immobilized onto the SSA biosensor surface. The analysis for each inhibitor was performed in duplicate at five different concentrations in 5% DMSO. Kinetic constants determined for these inhibitors agree well with literature values.

  • Immunogenic Response to a Drug

    Click Image To Enlarge +
    Figure 3. Resulting data from the enzyme–linked bridging assay protocol using the immunogenicity kit on the Octet RED

    Interaction analysis can also be used to monitor unwanted binding events such as the detection of undesirable immune responses to a therapeutic drug. The immune system may respond to drug administration in patients by producing antidrug antibodies (ADA). These ADAs could alter the pharmacodynamics and pharmacokinetics of the drug. ADAs can be produced in a wide range of concentrations and with a wide range of affinities.  To accurately detect these antibodies, the assay must have good sensitivity, withstand a wide range of free drug concentrations, and have minimal matrix effects. 

    The Octet system can be used with the available Dip and Read Immunogenicity Kit to detect ADAs in both human and animal samples. The assay is run without plate-washing steps allowing detection of low affinity antibodies that could be missed in ELISA type assays. Figure 3 shows data that demonstrates the ability of this assay to tolerate 500-fold excess of drug and still have sensitivity to 20 ng/mL of ADA.

Related content